AN2 Therapeutics Inc. (ANTX)
1.11
-0.03 (-2.63%)
At close: Mar 03, 2025, 12:12 PM
AN2 Therapeutics Balance Sheet Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Cash & Equivalents | 15.65M | 27.22M | 12.1M | 4.07M | 5.6M |
| Short-Term Investments | 91.65M | 68.84M | 46.46M | n/a | n/a |
| Long-Term Investments | 27.19M | 3.22M | 3.49M | n/a | n/a |
| Other Long-Term Assets | 1.04M | 667K | 1.72M | n/a | n/a |
| Receivables | n/a | n/a | n/a | n/a | n/a |
| Inventory | n/a | n/a | n/a | n/a | n/a |
| Other Current Assets | 3.21M | 2.56M | 1.55M | 164K | 102K |
| Total Current Assets | 110.51M | 98.62M | 60.11M | 4.23M | 5.7M |
| Property-Plant & Equipment | n/a | 53K | n/a | n/a | n/a |
| Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 28.24M | 3.94M | 5.21M | n/a | n/a |
| Total Assets | 138.74M | 102.56M | 65.32M | 4.23M | 5.7M |
| Account Payables | 2.68M | 2.12M | 1.06M | 132K | 51K |
| Deferred Revenue | n/a | n/a | n/a | n/a | n/a |
| Short-Term Debt | n/a | 106K | n/a | n/a | n/a |
| Other Current Liabilities | 11.37M | 4.96M | 2.33M | 1.33M | 108K |
| Total Current Liabilities | 14.04M | 7.19M | 3.4M | 1.46M | 159K |
| Long-Term Debt | n/a | n/a | n/a | n/a | 728K |
| Other Long-Term Liabilities | n/a | 2K | 109.33M | 23.09M | n/a |
| Total Long-Term Liabilities | n/a | 2K | 109.33M | 23.09M | 728K |
| Total Liabilities | 14.04M | 7.19M | 112.73M | 24.55M | 887K |
| Total Debt | n/a | 53K | n/a | n/a | 728K |
| Common Stock | n/a | n/a | n/a | n/a | n/a |
| Retained Earnings | -154.46M | -89.72M | -47.38M | -20.32M | -5.8M |
| Comprehensive Income | 275K | -374K | -27K | n/a | n/a |
| Shareholders Equity | 124.7M | 95.37M | -47.41M | -20.32M | 4.81M |
| Total Investments | 118.84M | 72.06M | 49.94M | n/a | n/a |